CTOs on the Move

Vigil Neuroscience

www.vigilneuro.com

 
Vigil Neuroscience is the world`s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain`s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vigilneuro.com
  • One Broadway Suite 07-300
    Cambridge, MA USA 02142
  • Phone: 857.254.4445

Executives

Name Title Contact Details

Funding

Vigil Neuroscience raised $50M on 12/08/2020

Similar Companies

Clinical DataFax Systems

Clinical DataFax Systems, Inc. is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Simcere Pharmaceuticals

Simcere Pharmaceuticals is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hollister Stier

Hollister Stier is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AdviNOW Medical

Our AI & AR powered technology reduces medical practice overhead, accelerates patient throughput, improves efficiency, and speeds up data collection.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.